#1 Clinical Trials Search in Europe

Belantamab Mafodotin

Belantamab mafodotin, also known as Blenrep, is an innovative drug being studied in clinical trials for the treatment of multiple myeloma and other blood cancers. This article examines ongoing research investigating its safety, efficacy, and optimal dosing regimens in various patient populations. We’ll explore how this targeted therapy is being evaluated as a monotherapy and in combination with other treatments across different stages of disease.

Table of Contents

What is Belantamab Mafodotin?

Belantamab Mafodotin, also known by its brand name Blenrep, is an innovative drug developed for the treatment of multiple myeloma, a type of blood cancer[1]. It belongs to a class of medications called antibody-drug conjugates (ADCs), which combine the targeting ability of antibodies with the cancer-killing power of chemotherapy drugs[1].

How Does It Work?

Belantamab Mafodotin works in a unique way to target cancer cells:

  • It targets a protein called B-cell maturation antigen (BCMA), which is found in high amounts on myeloma cells[2].
  • The antibody part of the drug attaches to BCMA on the surface of myeloma cells.
  • Once attached, the drug is taken into the cancer cell.
  • Inside the cell, the chemotherapy part (mafodotin) is released, killing the cancer cell[1].
This targeted approach helps to minimize damage to healthy cells, potentially reducing side effects compared to traditional chemotherapy.

Conditions Treated

Belantamab Mafodotin is primarily used to treat:

  • Multiple Myeloma: This is a type of blood cancer that affects plasma cells, a type of white blood cell that normally produces antibodies to fight infections[3].
  • Relapsed or Refractory Multiple Myeloma: This refers to cases where the cancer has returned after treatment or has not responded to other therapies[4].
In some clinical trials, it is also being studied for:
  • AL Amyloidosis: A rare disease caused by the buildup of abnormal proteins in various organs[5].
  • Plasmablastic Lymphoma: An aggressive type of non-Hodgkin lymphoma[1].
  • ALK+ Large B-Cell Lymphoma: Another type of aggressive lymphoma[1].

Administration and Dosage

Belantamab Mafodotin is typically administered as follows:

  • It is given as an intravenous (IV) infusion, meaning it’s delivered directly into the bloodstream through a vein[3].
  • The usual dose is 2.5 mg per kilogram of body weight[6].
  • It is often given every 3 weeks, but some studies are exploring different schedules, such as every 6 or 8 weeks[4][3].
  • Treatment continues until the disease progresses or unacceptable side effects occur[3].
The exact dosing schedule may vary depending on individual patient factors and the specific treatment plan.

Clinical Trials and Research

Belantamab Mafodotin is the subject of numerous clinical trials aimed at understanding its effectiveness and safety in various scenarios:

  • Newly Diagnosed Multiple Myeloma: Some trials are exploring its use in patients who have just been diagnosed, in combination with other drugs before and after stem cell transplantation[3].
  • Combination Therapies: Researchers are studying how Belantamab Mafodotin works when combined with other myeloma treatments like bortezomib, lenalidomide, and dexamethasone[3].
  • Maintenance Therapy: It’s being investigated as a maintenance treatment to help keep the cancer in remission after initial therapy[6].
  • Different Dosing Schedules: Studies are looking at various dosing regimens to find the optimal balance between effectiveness and side effects[7].
  • Special Patient Populations: There are trials focused on patients with liver problems to understand how the drug behaves in these individuals[8].
These ongoing studies will help refine how Belantamab Mafodotin is used in the future, potentially expanding its applications and improving patient outcomes.

Side Effects and Safety

Like all medications, Belantamab Mafodotin can cause side effects. Some of the most important ones to be aware of include:

  • Eye Problems: The most common and significant side effect is changes to the cornea (the clear front part of the eye). This can cause blurred vision, dry eyes, or other vision changes. Regular eye exams are required during treatment[2].
  • Fatigue: Feeling very tired is common with this treatment.
  • Blood Cell Count Changes: The drug can affect your blood cell counts, potentially increasing the risk of infections or bleeding[8].
  • Nausea and Vomiting: Some patients may experience these digestive system effects.
  • Fever: An increased body temperature can occur, especially after infusions.
It’s important to note that not everyone experiences all of these side effects, and many can be managed with proper medical care. Always report any new symptoms or changes in your health to your healthcare team.

Future Prospects

Belantamab Mafodotin represents an exciting advancement in the treatment of multiple myeloma and potentially other blood cancers. Ongoing research is focused on:

  • Optimizing its use in different stages of multiple myeloma treatment[3].
  • Exploring its effectiveness in combination with other therapies[3].
  • Investigating its potential in treating other types of cancer[1].
  • Developing strategies to manage and minimize side effects, particularly eye-related issues[7].
As research continues, Belantamab Mafodotin may become an increasingly important tool in the fight against multiple myeloma and other blood cancers, offering hope to patients who have limited treatment options.

Aspect Details
Drug Name Belantamab mafodotin (Blenrep)
Target B-cell maturation antigen (BCMA)
Primary Indications Relapsed/refractory multiple myeloma, AL amyloidosis, plasmablastic lymphoma, ALK+ large B-cell lymphoma
Administration Intravenous infusion, various dosing schedules (e.g., every 3, 6, or 8 weeks)
Key Outcomes Measured Overall response rate, progression-free survival, duration of response, overall survival, MRD negativity
Safety Monitoring Corneal events (KVA scale), hematological parameters, liver function, adverse events
Trial Phases Phase 1 and 2 studies
Special Populations Patients with hepatic impairment, elderly/frail patients
Combination Approaches Monotherapy and in combination with other treatments (e.g., dexamethasone)
Novel Applications Pre- and post-autologous stem cell transplant, maintenance therapy

FAQ

  • What is belantamab mafodotin and how does it work? Belantamab mafodotin is an antibody-drug conjugate that targets B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells. It works by using the antibody portion to enter cancer cells and then releasing a drug to kill them.
  • What types of cancer is belantamab mafodotin being studied for? It is primarily being studied for multiple myeloma, especially in patients with relapsed or refractory disease. Some trials are also exploring its use in other blood cancers like AL amyloidosis, plasmablastic lymphoma, and ALK-positive large B-cell lymphoma.
  • What are some of the potential side effects being monitored? Researchers are closely monitoring for corneal events (changes to the eye), which are graded using the KVA scale. Other potential side effects include changes in blood cell counts, liver function, and general adverse events. Eye exams and laboratory tests are regularly performed to assess safety.
  • How is belantamab mafodotin given to patients? It is typically given as an intravenous infusion. The dosing schedule varies between trials, with some administering it every 3 weeks and others exploring longer intervals like every 6 or 8 weeks. Dose levels are often based on the patient's body weight.
  • What are some of the outcomes researchers are measuring in these trials? Key outcomes include overall response rate, progression-free survival, duration of response, and overall survival. Researchers are also assessing minimal residual disease negativity, quality of life measures, and various pharmacokinetic parameters to understand how the drug behaves in the body.

Ongoing Clinical Trials on Belantamab Mafodotin

  • Study of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France Norway Poland Sweden

  • Study of belantamab mafodotin, bortezomib and dexamethasone combination in adults with relapsed or refractory multiple myeloma who received at least one prior therapy

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia

  • Study on Belantamab Mafodotin with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Greece

  • Study of belantamab mafodotin with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Study on Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1
    Investigated drugs:
    France Germany Greece Ireland Italy Poland +1

  • Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia France Germany Greece Italy Poland +1

  • Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Italy Norway

  • Study of Belantamab Mafodotin, Carfilzomib, and Dexamethasone for Patients with Relapsed Multiple Myeloma Resistant to Lenalidomide

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Antibody-drug conjugate (ADC): A type of targeted cancer therapy that combines a monoclonal antibody with a potent anti-cancer drug. The antibody helps deliver the drug directly to cancer cells.
  • B-cell maturation antigen (BCMA): A protein found on the surface of plasma cells and some B cells. It is often targeted in multiple myeloma treatments.
  • Keratopathy visual acuity (KVA) scale: A grading system used to assess corneal events and changes in visual acuity in patients receiving certain treatments like belantamab mafodotin.
  • Minimal residual disease (MRD): The small number of cancer cells that may remain in the body during or after treatment. MRD negativity is often a treatment goal.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Relapsed/refractory multiple myeloma (RRMM): Multiple myeloma that has returned after treatment or does not respond to treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Autologous stem cell transplant (ASCT): A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help restore the bone marrow.
  • AL amyloidosis: A rare disease where abnormal proteins build up in organs and tissues, often associated with plasma cell disorders.

References